Pros and cons of antibiotic therapy for pouchitis

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 5, 2009, Pages 547-559

  Navaneethan, Udayakumar ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antibiotic; Ileal pouch anal anastomosis; Inflammatory bowel disease; Pouchitis; Trial

Indexed keywords

ADALIMUMAB; ALCOHOL; ANTIBIOTIC AGENT; AZATHIOPRINE; BISMUTH; BUDESONIDE; BUTYRIC ACID; CIPROFLOXACIN; DNA DIRECTED RNA POLYMERASE; GLUTAMINE; HYDROGEN SULFIDE; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SULFOMUCIN; TINIDAZOLE; VSL3;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ACHILLES REFLEX; ALGORITHM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BACTERIAL FLORA; BACTERIAL TRANSLOCATION; BRAIN DISEASE; CHOLANGITIS; CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS; CHRONIC POUCHITIS; CHRONIC REFRACTORY POUCHITIS; CLINICAL PRACTICE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CROSS RESISTANCE; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DNA SYNTHESIS INHIBITION; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FECES CULTURE; GASTROINTESTINAL TOXICITY; GLYCOPROTEIN SYNTHESIS; HEADACHE; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; INFECTION RISK; INSOMNIA; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREGNANCY; QUALITY OF LIFE; REMISSION; REVIEW; SECONDARY INFECTION; SECONDARY PREVENTION; SEIZURE; SIDE EFFECT; SULFATE REDUCING BACTERIUM; SULFOMUCIN PRODUCTION; TENDINITIS; TENDON RUPTURE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; POUCHITIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70449718866     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.37     Document Type: Review

References (83)

1. Fazio VW, Ziv Y, Church JM et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann. Surg. 222, 120-127 (1995).
2. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 107, 1856-1860 (1994).
3. Coffey JC, Winter DC, Neary P et al. Quality of life after ileal pouch - anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis. Colon Rectum 45, 30-38 (2002). (Pubitemid 34072749)
4. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol. Clin. North Am. 30, 223-241 (2001).
5. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin. Proc. 69, 409-415 (1994).
6. Keighley MR. Review article: the management of pouchitis. Aliment. Pharmacol. Ther. 10, 449-457 (1996).
7. Mowschenson PM, Critchlow JF, Peppercorn MA. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch. Surg. 135, 463-465 (2000).
8. Hurst RD, Chung TP, Rubin M, Michelassi F. Implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm. Bowel Dis. 4, 280-284 (1998). (Pubitemid 128699867)
9. Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J. Royal Coll. Surg. Edinburgh 46, 334-337 (2001).
10. Lohmuller JL, Pemberton HJ, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann. Surg. 211, 622-629 (1990). (Pubitemid 20155701)
11. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch. Surg. 131, 497-500; discussion 501-502 (1996). (Pubitemid 26136371)
12. Ohge H, Furne JK, Springfield J et al. Association between fecal hydrogen sulfide production and pouchitis. Dis. Colon Rectum 48, 469-475 (2005). (Pubitemid 40767867)
13. Gosselink MP, Schouten WR, van Lieshout LM et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis. Colon Rectum 47, 1519-1525 (2004).
14. Shen B, Fazio VW, Remzi FH et al. Risk factors for diseases of ileal pouch - anal anastomosis in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 4, 81-89 (2006). (Pubitemid 43129528)
15. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig. Dis. Sci. 39, 1193-1196 (1994).
16. Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis. 7, 301-305(2001). • Randomized, comparative study of ciprofloxacin and metronidazole in acute pouchitis. (Pubitemid 33062095)
17. Sambuelli A, Boerr L, Negreira S et al. Budesonide enema in pouchitis - a double-blind, double-dummy, controlled trial. Aliment. Pharmacol. Ther. 16, 27-34 (2002). (Pubitemid 34123861)
18. Kühbacher T, Ott SJ, Helwig U et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55, 833-841 (2006). • Demonstrates an alteration in the fungal microbiota in pouchitis. (Pubitemid 43764555)
19. Shen B, Jiang Z-D, Fazio VW et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol. 6,782-788 (2008).
20. Penna C, Tiret E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br. J. Surg. 80, 765-767 (1993). (Pubitemid 23197736)
21. Tjandra JJ, Fazio VW, Church JM, Oakley JR, Milsom JW, Lavery IC. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am. J. Surg. 165, 322-325 (1993).
22. Coffey JC, Rowan F, Burke J, Dochery NG, Kirwan WO, O'Connell PR. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am. J. Gastroenterol. 104, 1013-1023 (2009).
23. Shepherd NA, Jass JR, Duval I et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J. Clin. Pathol. 40, 601-607 (1987). (Pubitemid 17092838)
24. Humphries DE, Silbert CK, Silbert JE. Glycosaminoglycan production by bovine aortic endothelial cells cultured in sulfate-depleted medium. J. Biol. Chem. 261, 9122-9127 (1986).
25. Smith FM, Coffey JC, Kell MR et al. A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis. 7, 563-570 (2005).
26. Kmiot WA, Williams MR, Keighley MR. Pouchitis following colectomy and ileal reservoir construction for familial adenomatous polyposis. Br. J. Surg. 77, 1283 (1990).
27. Ohge H, Takesue Y, Sueda T et al. [Fecal hydrogen sulfide: toxin? Or just odoriferous gas?]. Jpn. J. Antibiotics 58, 193-199 (2005).
28. de Silva HJ, Gatter KC, Millard PR et al. Crypt cell proliferation and HLA-DR expression in pelvic ileal pouches. J. Clin. Pathol. 43, 824-828 (1990).
29. Deplancke B, Finster K, Graham WV et al. Gastrointestinal and microbial responses to sulfate-supplemented drinking water in mice. Exp. Biol. Med. (Maywood) 228, 424-433 (2003). (Pubitemid 37203650)
30. Sandborn WJ. Pouchitis: risk factors, frequency, natural history, classification and public health prospective. In: Trends in Inflammatory Bowel Disease 1996. McLeod RS, Martin F, Sutherland LR, Wallace JL, Williams CN (Eds). Kluwer Academic Publishers, Lancaster, UK, 51-63 (1997).
31. Shen B. Diagnosis and management of patients with pouchitis. Drugs 65, 453-461(2003).
32. Duffy M, O'Mahony L, Coffey JC et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis. Colon Rectum 45, 384-388 (2002). (Pubitemid 34273621)
33. Komanduri S, Gillevet PM, Sikaroodi M et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin. Gastroenterol. Hepatol. 5, 352-360 (2007). (Pubitemid 46401536)
34. Shen B, Fazio VW, Remzi FH et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am. J. Gastroenterol. 100, 93-101 (2005). • Comprehensive clinical, endoscopic and histologic evaluations of pouchitis. (Pubitemid 41623275)
35. Shepherd NA, Hulten L, Tytgat GN et al. Workshop: pouchitis. Int. J. Colorectal Dis. 4, 205-229 (1989).
36. Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig. Dis. 15, 172-188 (1997).
37. Kmiot WA, Youngs D, Tudor R, Thompson H, Keighley MR. Mucosal morphology, cell proliferation and fecal bacteriology in acute pouchitis. Br. J. Surg. 80, 1445-1449 (1993). (Pubitemid 23345115)
38. Bell AJ, Nicholls RJ, Forbes A, Ellis HJ, Ciclitira PJ. Human lymphocyte stimulation with pouchitis flora is greater than with flora from a healthy pouch but is suppressed by metronidazole. Gut 53, 1801-1805 (2004).
39. Sagar PM, Taylor BA, Godwin P et al. Acute pouchitis and deficiencies of fuel. Dis. Colon Rectum 38, 488-493 (1995).
40. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev. Anti Infect. Ther. 4, 417-427 (2006).
41. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 73(Suppl. 1), 13-27 (2006). (Pubitemid 43296214)
42. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66, 246-1245 (2002). (Pubitemid 36578775)
43. Riva S, Fietta A, Berti M, Silvestri LG, Romero E. Relationships between curing of the F episome by rifampin and by acridine orange in Escherichia coli. Antimicrob. Agents Chemother. 3, 456-462 (1973).
44. Huang DB, DuPont HL. Rifaximin - a novel antimicrobial for enteric infections. J. Infect. 50, 97-106 (2005).
45. Isaacs KL, Sandler RS, Abreu M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 13, 1250-1255 (2007). • First randomized, controlled trial of rifaximin in active pouchitis. (Pubitemid 47597772)
46. Baidoo L, Kundu R, Su C et al. Rifaximin is an effective antibiotic for the treatment of pouchitis [abstract]. Gastroenterology 128(4 Suppl. 2), A797 (2005).
47. McLaughlin SD, Clark SK, Bell AJ, Tekkis PP, Ciclitira PJ, Nicholls RJ. An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment. Pharmacol. Ther. 29(1), 69-74 (2008).
48. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3®) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108-114(2004). (Pubitemid 38083018)
49. Shen B, Brzezinski A, Fazio VW et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis - experience in clinical practice. Aliment. Pharmacol. Ther. 22, 721-728(2005). (Pubitemid 41475334)
50. McLaughlin SD, Johnson MW, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ. VSL#3 for chronic pouchitis; experience in UK clinical practice [abstract]. Gastroenterology 134(Suppl. 1), A711 (2008).
51. Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 8, 26 (2008). • Open-labeled trial of antibiotics in antibiotic-dependent pouchitis. (Pubitemid 351998102)
52. Shen B, Fazio VW, Remzi FH et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig. Dis. Sci. 52, 3321-3328 (2007). (Pubitemid 350077174)
53. Munoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of ileoanal pouch as a refractory idiopathic chronic pouchitis. Report of two cases. Dis. Colon Rectum 42, 117-120 (1999). (Pubitemid 29053131)
54. Shen B, Remzi FH, Nutter B et al. Association between immune-associated disorders and adverse outcomes of ileal pouch-anal anastomosis. Am. J. Gastroenterol. 104, 655-664 (2009). •• Possible autoimmune association of chronic antibiotic refractory pouchitis.
55. McLaughlin SD, Clark SK, Shafi S et al. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin. Gastroenterol. Hepatol. 7, 545-548 (2009). •• First study to report the role of fecal coliform sensitivity test in the diagnostic work-up and appropriate treatment in patients with chronic antibiotic-refractory pouchitis.
56. Shen B, Fazio V, Remzi F et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis. Col. Rectum 50, 498-508 (2007). (Pubitemid 46701616)
57. Mimura T, Rizzello F, Helwig U et al. Four-week open label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment. Pharmacol. Ther. 16, 909-917 (2002). (Pubitemid 34461760)
58. Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment. Pharmacol. Ther. 13, 713-718 (1999). (Pubitemid 29276839)
59. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis. 7, 182-186 (2005).
60. Kornbluth A, Hunt M, George J, Legnani P. An open label pilot trial of rifaximin in the treatment of patients with refractory pouchitis [abstract]. Gastroenterology 130(4 Suppl. 2), A658 (2006).
61. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124, 1202-1209 (2003). • Randomized, double-blind, placebo-controlled study of probiotics for the primary prophylaxis of pouchitis. (Pubitemid 36531796)
62. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119, 305-309 (2000). (Pubitemid 30621980)
63. Pronio A, Montesani C, Butteroni C et al. Probiotic administration in patients with ileal pouch - anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis. 14, 662-668 (2008). (Pubitemid 351742983)
64. Gionchetti P, Rizzello F, Poggioli G et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment. Pharmacol. Ther. 25, 1231-1236 (2007). (Pubitemid 46650294)
65. Calabrese C, Gionchetti P, Rizzello F et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment. Pharmacol. Ther. 27, 759-764 (2008).
66. Viscido A, Kohn A, Papi C, Caprilli R. Management of refractory fistulizing pouchitis with infliximab. Eur. Rev. Med. Pharmacol. Sci. 8, 239-246 (2004). (Pubitemid 39654528)
67. Shen B, Remzi FH, Lavery IC et al. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment. Pharmacol. Ther. 29, 519-526 (2009).
68. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch - anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin. Proc. 68, 978-981 (1993). (Pubitemid 23295440)
69. Gionchetti P, Rizzello F, Venturi A et al. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment. Pharmacol. Ther. 11, 673-678 (1997). (Pubitemid 27376353)
70. Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 11, 1041-1046 (1997).
71. Kapoor K, Chandra M, Nag D et al. Evaluation of metronidazole toxicity: a prospective study. Int. J. Clin. Pharmacol. Res. 19, 83-88 (1999). (Pubitemid 30162679)
72. Raether W, Hänel H. Nitroheterocyclic drugs with broad-spectrum activity. Parasitol. Res. 90(Suppl.), 19-39 (2003).
73. Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection - an unusual cause of refractory pouchitis: report of a case. Dis. Colon Rectum 46, 267-270 (2003). (Pubitemid 36222627)
74. Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig. Dis. Sci. 51, 2361-2364 (2006).
75. Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin. Ther. 27, 1859-1884 (2005).
76. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61, 377-392 (1997).
77. Mandell LA. Improved safety profile of newer fluoroquinolone. In: Fluoroquinolone Antibiotics. Ronald AR, Low DE (Eds). Birkhäuser, Basel, Switzerland, 73-86 (2003).
78. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254-1260 (2005). (Pubitemid 41532667)
79. Soro O, Pesce A, Raggi M, Debbia EA, Schito GC. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin. Microbiol. Infect. 3, 147-151 (1997). (Pubitemid 27163144)
80. Malvisi Stracciari J, Venturini AP, Anfossi P, Marchi E, Stracciari GL. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia 6, 82-84 (1987). (Pubitemid 17094031)
81. Shen B, Achkar J-P, Lashner BA et al. Endoscopic and histologic evaluation together with symptom assessment is required to diagnose pouchitis. Gastroenterology 121, 261-267 (2001). (Pubitemid 32729373)
82. Shen B, Achkar JP, Lashner BA et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am. J. Gastroenterol 97, 972-977 (2002). (Pubitemid 34408256)
83. Shen B, Shermock KM, Fazio VW et al. A cost-effectiveness ana lysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis. Am. J. Gastroenterol. 98, 2460-2467 (2003). (Pubitemid 37448757)